Position
Creative Planning in Theravance Biopharma, Inc.
Back to the book · All holders of TBPH
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$35.6K$18.71 → $16.23
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 14.4K | $268.9K | — | — | — | 0.0% |
| Q1 2026 | 16.5K | $267.3K | $16.23 | −$35.6K | $34K | 0.0% |